Literature DB >> 10518080

Corticosteroids in the treatment of the acute phase of Kawasaki disease.

M Shinohara1, K Sone, T Tomomasa, A Morikawa.   

Abstract

OBJECTIVES: Corticosteroids are considered to be contraindicated during the acute phase of Kawasaki disease (KD) based on unfavorable results in early studies. In our hospital, however, corticosteroids have been used in some cases of KD with satisfactory results. We analyzed outcomes of patients with KD treated with or without corticosteroids. STUDY
DESIGN: Medical records of 299 children with KD treated with one of the 4 regimens were reviewed retrospectively. Regimen 1 consisted of aspirin, dipyridamole, and propranolol; regimen 2 was regimen 1 plus prednisolone, 2 mg/kg/d, for 1 week, followed by tapering over 2 weeks; regimen 3 was regimen 1 plus intravenous gamma-globulin (IVGG), 200 or 400 mg/kg/d, for 5 consecutive days; and regimen 4 was regimen 1 plus both prednisolone and IVGG.
RESULTS: Although patients treated with regimens 2 and 4 were more ill at presentation than those treated with regimens 1 and 3, respectively, the duration of fever was shorter in the former patient groups (P =.0013). Coronary aneurysms developed least frequently in patients treated with regimen 4 and less frequently with regimen 2 than with regimen 1 (P =.0730). Multiple regression analysis showed significant reductions of fever and coronary aneurysm incidence with prednisolone (P <.0001 and P =.0307, respectively).
CONCLUSION: Our data suggest a possible role of corticosteroids in the treatment of the acute phase of KD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10518080     DOI: 10.1016/s0022-3476(99)70169-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 3.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

4.  Regulation of oxidative stress in patients with Kawasaki disease.

Authors:  Kaori Sekine; Hiroyuki Mochizuki; Yoshinari Inoue; Tohru Kobayashi; Eisuke Suganuma; Shinichi Matsuda; Hirokazu Arakawa
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 5.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.

Authors:  H Senzaki
Journal:  Arch Dis Child       Date:  2006-10       Impact factor: 3.791

7.  Recognizing Kawasaki disease.

Authors:  B Lang
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

Review 8.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

9.  Kawasaki disease at British Columbia's Children's Hospital.

Authors:  Regan L Ebbeson; Mark R Riley; Jim E Potts; Derek G Human; Peter N Malleson
Journal:  Paediatr Child Health       Date:  2004-09       Impact factor: 2.253

10.  Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.

Authors:  Toshiaki Jibiki; Masaru Terai; Tomomichi Kurosaki; Hiromichi Nakajima; Kazuhiro Suzuki; Hiroaki Inomata; Itaru Terashima; Takafumi Honda; Kumi Yasukawa; Hiromichi Hamada; Yoichi Kohno
Journal:  Eur J Pediatr       Date:  2004-02-13       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.